The US Food and Drug Administration (FDA) has issued an important update to alert healthcare providers regarding the expansion of the list of medical care devices manufactured in Japan by Olympus Medical Systems Corporation and its affiliates, which have been subjected to an official import ban preventing their entry into the territory of the United States of America.
This new action follows ongoing and protracted efforts to address compliance issues, as US regulators continue to express serious concerns regarding the existence of ongoing and persistent violations of Quality System Regulations by the manufacturer, necessitating the activation of the import ban under Import Alert 89-04.
Expansion of Banned Devices
The import ban includes a wide range of biomedical devices intended for precise diagnostic and therapeutic uses, including:
- Ureterorenoscopes: Used in diagnostic and therapeutic procedures of the urinary tract.
- Bronchoscopes: Intended for respiratory tract examination and internal therapeutic interventions.
- Laparoscopes: Used in laparoscopic abdominal surgeries.
- Automated Endoscope Reprocessors: Necessary for cleaning and sterilizing medical endoscopes.
- Ingestible telemetric gastrointestinal capsule imaging systems: Intended for visualization of the small intestine mucosa.
- Enteroscopes: To provide visualization and perform procedures within the small intestine.
What Changes Practically for Healthcare Providers?
The FDA provided clear guidance to healthcare facilities and physicians regarding the handling of these devices currently in service:
- Continued use of existing devices: Users are permitted to continue using the banned devices currently in their possession, provided they do not encounter any operational issues, with strict adherence to sterilization instructions, cleaning protocols, and routine maintenance guidelines.
- Avoiding damaged devices: The use of damaged devices or those that have failed leak tests is strictly prohibited due to being a potential source of contamination.
- Managing recalls: In the event that devices are covered by previous recalls, manufacturer customer notices must be followed precisely.
- Risk-benefit assessment: The FDA does not recommend canceling or delaying medical procedures without a thorough discussion of benefits and risks between the physician and the patient, alongside the necessity of immediately reporting any adverse events through the MedWatch program.
Regulatory Background and Follow-up History
This decision reflects a series of Warning Letters issued by the FDA against various manufacturing sites belonging to Olympus in Japan (such as the Aizu, Hachioji-shi, and Hinode facilities) during previous years, due to deficiencies in current good manufacturing practices (CGMP) and medical device reporting requirements. It is worth noting that spare parts, connectors, and single-use consumables not subject to direct regulatory rules remain exempt from the current import restrictions.